Pulmonary arterial hypertension (PAH) is a devastating condition characterized by progressive symptoms, right heart failure, and death (1, 2) . In the 1980s, the NIH Registry for the Characterization of Primary Pulmonary Hypertension reported a median survival of 2.8 years in untreated patients (3) . Since then, advances in medical therapies targeting dysfunctional nitric oxide, endothelin 1, and prostacyclin pathways have dramatically improved the prognosis of PAH (4, 5) ; however, longterm survival remains poor (6) .
To accurately prognosticate and inform treatment decisions, clinicians must assess the risk of a poor outcome for each patient. The goals of PAH treatments are to reduce symptoms, improve quality of life, delay the progression of disease, and reduce the risk of a poor outcome, such as death or the need for lung transplant (7) . Risk stratification is dependent on several patient factors, including age, sex, etiology of PAH, functional capacity, right ventricular (RV) function, and hemodynamic variables. Some of these factors, such as exercise capacity, RV function, and hemodynamic variables can be modified or improved with treatment (7) (8) (9) . No single attribute among these is adequate to estimate the risk; however, a combination of such factors is routinely used to predict risk. Several multidimensional tools have been developed to predict prognosis (1-3, 8, 9) . Recent studies support that a "low-risk" patient profile can be achieved after initial treatment of PAH and that a low-risk profile is associated with better survival (10) (11) (12) (13) .
A recent statement from the NHLBI emphasized the need for a precision medicine approach to develop innovative new personalized therapies in PAH (14) . Future clinical trials in the era of precision medicine will need to have more meaningful endpoints that reflect patient-reported symptoms and function, in addition to survival (14) . The objectives of this article are 1) to review current methods for performing multidimensional risk assessment in PAH; 2) to justify the rationale for and potential limitations of using a low-risk profile in clinical trial endpoint designs; 3) to propose methods for how the low-risk profile could be validated as a surrogate outcome in PAH; and 4) to propose definitions for low-risk profile primary endpoints that could be used in future PAH clinical trials.
Prognostication in PAH and the "Low-Risk Profile"
Prospective registries have provided important insights into factors that are associated with improved survival in PAH, and several predictive equations have been derived to estimate the probability of survival for an individual patient (3, 8, 9, (15) (16) (17) . The concepts of individual patient risk assessment and stratification have been endorsed in American (18) and international (1, 2) (1, 2, 19) . Both tools are well validated and incorporate a combination of variables reflecting symptoms, functional capacity, imaging, biomarkers, and hemodynamics to risk stratify patients. In addition to providing prognostic information, these tools could be used to define treatment objectives with the ideal goal of obtaining a "low-risk" profile (1, 2, 4).
The REVEAL score is a risk assessment tool derived from a large (n = 2,716) prospective U.S. cohort of patients with various etiologies of PAH (8) . The REVEAL equation has been externally validated (20) (21) (22) and is accurate in newly diagnosed Definition of abbreviations: 6MWD = 6-minute-walk distance; APAH = associated PAH; BNP = brain natriuretic peptide; CI = cardiac index; CPET = cardiopulmonary exercise testing; CTD = connective tissue disease; ERS = European Respiratory Society; ESC = European Society of Cardiology; FPAH = familial PAH; HR = heart rate; MRI = magnetic resonance imaging; NT-proBNP = N-terminal pro-brain natriuretic peptide; NYHA = New York Heart Association; PAH = pulmonary arterial hypertension; PFT = pulmonary function test; PoPH = portopulmonary hypertension; PVR = pulmonary vascular resistance; RA = right atrium; RAP = right atrial pressure; REVEAL = Registry to Evaluate Early and Long-term PAH Disease Management; RHC = right heart catheterization; SBP = systolic blood pressure; Sv O 2 = mixed venous oxygen saturation; WHO = World Health Organization. The REVEAL score starts with a baseline score of 6. Each row has variables with a score between 22 to 12, depending on its prognostic weight. The sum of these scores is added to the baseline score of 6 to obtain the final REVEAL score. The ESC/ERS part of the patients (19) and for serial follow-up assessments (10) . The simplified REVEAL calculator includes 12 variables that deliver a total score between 1 and 22 ( Table 1 ) and estimate 1-year survival according to five risk groups ( Figure 1A) . A patient newly diagnosed with PAH with a REVEAL score of 1-7 is considered low risk and has an estimated 1-year survival greater than 95%, whereas a patient with a score greater than or equal to 10 is at high risk and has an estimated 1-year survival of 66 to 72% (19) .
In contrast to REVEAL, the recently proposed ESC/ERS risk assessment Number at risk Log rank, p<0.001
Stable "Low risk" Improve to "Low risk"
Worsened to "Intermediate risk" or "High risk" cutoff points for each variable are based on previous studies, including those from REVEAL, and on consensus expert opinion. Three recent studies have independently validated the ESC/ERS risk assessment tool in contemporary European PAH cohorts (11) (12) (13) .
Kylhammar and colleagues applied the ESC/ERS risk assessment tool to 530 patients in the Swedish PAH registry (11 (13) . They also showed that the ESC/ERS tool effectively discriminated survival groups at baseline and during followup, and that it was valid in a subgroup of patients with connective tissue disease-associated PAH. A study using the French PAH registry by Boucly and colleagues employed a different approach to validate the ESC/ERS risk assessment tool by calculating the number of low-risk criteria present for a selected number of variables (WHO functional class, 6MWD, right atrial pressure, and cardiac index) (12) . Among 1,017 patients with idiopathic, drug-induced, and heritable PAH, survival differed according to the number of low-risk criteria present at baseline, with better discrimination observed with the number of low-risk criteria present at first follow-up ( Figure 1B ). More than 93% of patients who had achieved three or four low-risk criteria within a median time to follow-up of 4.4 months were still alive at 3 years.
Importantly, in all three European studies (11-13) and a recent REVEAL study (10) , patients who improved to a lower-risk profile at follow-up had better outcomes than those who did not improve ( Figure 1C) . Patients who remain "stable" in the intermediate-risk group have poorer outcomes, suggesting that stability should not be considered as an acceptable treatment outcome. Patients who were intermediate or high risk at baseline but improved to low risk had outcomes similar to those of patients who started as low risk and remained at low risk. This confirmed previous findings suggesting that assessment after initial treatment might be more important than baseline risk assessment in newly diagnosed patients (23, 24) . In all three European studies, a minority of patients actually achieved a low-risk profile by the time of follow-up assessment: 30% in the Swedish study by Kylhammar and colleagues, 24% in the COMPERA study by Hoeper and colleagues, and 41.5% in the French study by Boucly and colleagues (11) (12) (13) . In a REVEAL study by Benza and colleagues, at 12 months from enrollment, 32% of patients had a decrease (improvement) in their REVEAL scores, and 51% were low risk (REVEAL score, ,8) (10). However, only approximately 15 to 50% received initial dual-or triple-combination therapy in the European and REVEAL studies. Whether increased use of initial combination therapy will translate to more patients achieving a low-risk profile remains to be studied; however, in our study using the French registry, we reported the highest use of initial combination therapy (approximately half of patients) and the highest proportion of patients with a lowrisk profile at follow-up (41.5%) (12) .
A valid risk assessment tool using strictly noninvasive variables would be ideal. Cogswell and colleagues showed that an abbreviated version of the REVEAL score, which excluded hemodynamic variables and DL CO , performed similarly to the full REVEAL score in predicting survival at 1 year (25) . In a subgroup analysis by Boucly and colleagues of 603 patients in the French study, who had BNP or NT-proBNP measurements within the first year of treatment, the presence of all three noninvasive low-risk criteria (WHO functional class I or II, 6MWD .440 m, and BNP ,50 ng/L or NT-proBNP ,300 ng/L) also identified a group of patients with excellent short-and long-term survival ( Figure 1D ) (12) .
Despite its simplicity and consistency, some important limitations remain regarding the ESC/ERS risk tool. Although the European registries were established prospectively, the analyses were retrospective, there was significant loss to follow-up, and the ESC/ERS approach still needs to be validated prospectively and in prevalent cohorts. Unlike the REVEAL score, the individual criteria in the ESC/ERS table are not weighted according to relative importance, and it is not known whether the ESC/ERS tool predicts clinical worsening or hospitalizations. The French approach of quantifying the number of low-risk criteria has not yet been studied in PAH associated with other medical conditions (i.e., connective tissue diseases). The REVEAL score also needs prospective validation and contains certain variables in the score that are infrequently observed (i.e., pulmonary vascular resistance .32 Wood units); however, a new version of the REVEAL score has recently been proposed and may overcome some of these perceived shortcomings (26) . A final limitation of both approaches is the lack of data demonstrating the ability to discriminate risk at the bedside for an individual patient in terms of positive and negative predictive values.
Rationale for Considering the Low-Risk Profile as a Clinical Trial Endpoint
Primary endpoints in PAH clinical trials must be 1) clinically relevant, 2) sensitive to a treatment or intervention, and 3) reproducible and easily interpretable (27, 28) . The sample size calculation for a clinical trial depends on the specified type 1 (false-positive) and type 2 (false-negative) error rates, the effect size on the primary endpoint that is considered important to detect, and the anticipated frequency of the primary endpoint in the control arm (29) . Most pivotal pharmaceutical clinical trials in PAH have used the change in 6MWD over a short-term duration as the primary outcome (30) . However, authors of a meta-analysis of 22 randomized controlled trials published between 1990 and 2011 found that changes in 6MWD were not predictive of long-term outcomes, including all-cause mortality, PAH-related hospitalization, or need for additional rescue therapy (31) . Similarly, changes in 6MWD and hemodynamic variables are not associated with long-term outcomes (32, 33) , whereas the achievement of an absolute value of 6MWD greater than 380-440 meters or cardiac index greater than or equal to 2.5 L/min/m 2 does appear to predict outcome (8, 11-13, 23, 24, 33) .
Death is a relatively infrequent and late occurrence in the disease course, which makes it difficult to adequately power a clinical trial to detect an effect on mortality.
Although the long-term survival of patients with PAH in contemporary registries remains suboptimal, it has improved from the days of the NIH Registry for the Characterization of Primary Pulmonary Hypertension (3, 6, 9), owing to many factors, including earlier diagnosis, improved general medical care, the development of targeted PAH treatment options, and the advent of initial and sequential combination therapy (34) (35) (36) . Death is often preceded by clinical worsening or a hospitalization for PAH (37, 38) ; therefore, composite endpoints, including hospitalization for PAH or clinical worsening of PAH, have been used to increase the overall event rate in recent clinical trials. This permits a smaller, more feasible trial than one powered to detect an effect on mortality. Some trials have employed composite endpoints such as the time to clinical worsening (TTCW) or a time to a composite endpoint of a first morbidity event or mortality. The definitions of these composite endpoints have varied between studies, limiting comparability (28) . Proper adjudication of nonfatal events within a composite endpoint is important, and weighing the individual components according to their severity and impact is likely more appropriate for trials in cardiovascular diseases (39, 40) . Composite endpoints in recent PAH trials have been driven by "softer" or less severe events, and the components of these composite outcomes have not been weighed according to relative impact or importance ( Figure 2) (34, 41, 42) .
It is now unethical to have a placebo-only (i.e., untreated) control arm in PAH trials. In the AMBITION (Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension) study, an upfront dual oral therapy strategy reduced the composite endpoint of morbidity/mortality events by 50% compared with oral monotherapy, an outcome that was driven largely by a reduction in PAH hospitalizations (34) . Consistent benefits have been reported in registry-based studies and a meta-analysis using sequential or initial combination therapy compared with monotherapy (35, 36, 43, 44) . As initial combination treatment becomes the standard of care, and if this strategy does decrease the risk of death (44), mortality and hospitalization rates in the control arms of future trials are likely to be even lower than in recent phase III randomized controlled trials (34, 41, 42) . A recent analysis of PAH-related hospitalizations in the Unites States between 2001 and 2012 confirmed a significant decrease in the number of hospitalizations over time (45) . Because the size of a trial depends on the event rate in the control arm, it will become increasingly difficult to adequately power trials to detect an effect on morbidity events and mortality. This would logically necessitate even larger and longerduration trials. With longer trial duration, crossover between intervention arms and patient dropout tend to increase, which results in a smaller effect size estimate in an intentionto-treat analysis and a loss of statistical power, respectively. Given the cost and logistical burden in undertaking and conducting long-term multinational clinical trials in a rare disease such as PAH, it may become necessary to develop alternative composite endpoints or establish new surrogate endpoints that reliably reflect the short-and long-term risks of "hard endpoints" such as death or lung transplant.
So far, there are no well-validated surrogates for short-or long-term clinical outcomes in PAH (46) . Ventetuolo and colleagues (47) pooled individual-level patient data from four short-term randomized trials and found that neither changes in hemodynamic variables nor the achievement of an absolute threshold for cardiac index explained the treatmentrelated effect on short-term clinical outcomes. At best, change in pulmonary vascular resistance accounted for 13.9% of the treatment effect on a clinical composite outcome. The results were unchanged after adjusting for New York Heart Association (NYHA) functional class and when limited to patients achieving a 6MWD greater than 380 meters by 12 weeks. The conclusion of that study, comprising over 1,000 trial patients with PAH, was that hemodynamic variables, on their own, are not acceptable surrogates for short-term clinical outcomes (47) . The implications of that study are important but do not necessarily dissuade the consideration of a multiparameter risk score as a trial outcome. Notably, only short-duration trials comparing monotherapy versus placebo were included in the Ventetuolo and colleagues meta-analysis. It is possible that these trials did not use the most important hemodynamic variables (47, 48) or that hemodynamic changes did not explain short-term outcomes but did explain long-term clinical outcomes. This latter hypothesis may be difficult to test in a similar manner using individual-level meta-analysis of existing trials, given that recent longer-term clinical trials did not include repeat hemodynamic assessments (24, 34, 41, 42 ). Establishing individual patient-level and trial-level surrogacy is challenging, especially in a rare disease. It would require a large trial or meta-analysis of several future trials to determine whether treatment effects on the true endpoint (i.e., death, transplant, or hospitalization) can be predicted on the basis of treatmentrelated effects on the risk profile or risk score (49, 50) . If a hemodynamic variable or multiparameter risk profile score (even one excluding hemodynamic variables) explained a large proportion of treatment-related Composite endpoints of morbidity/mortality events in recent phase III randomized clinical trials in pulmonary arterial hypertension (PAH) were driven mostly by hospitalizations and disease worsening rather than by more serious but less frequent events such as lung transplant or death (34, 41, 42 
Goal-oriented Treatment and the Future of PAH Clinical Trials
The low-risk profile is not yet ready for use as a primary trial endpoint, but there are foreseeable advantages that justify further investigation. First, it represents an opportunity for a philosophical shift toward goal-oriented therapy in clinical trial design rather than accepting the absence of a poor outcome as being sufficient. Clinical stability has been considered a therapeutic success in PAH; however, stable intermediate-or high-risk patients have worse long-term survival (10-13), and patients may not consider stability as an acceptable treatment goal. Trials using TTCW and morbidity/mortality composite endpoints were designed to detect the ability of an intervention to decrease or delay the occurrence of a poor outcome, rather than optimizing clinical response or obtaining a low-risk profile. Second, because a low-risk profile using the ESC/ERS tool and/or a low-risk REVEAL score (,8) are associated with lower shortand long-term risks of death, they represent novel candidate surrogates for "hard outcomes." As discussed in the previous section, despite strong associations in observational studies, it cannot be inferred that obtaining multiple low-risk treatment goals or a low-risk score will translate into improved long-term "hard outcomes." In patients with congestive heart failure, a BNP-guided strategy did not improve outcomes compared with a symptomguided strategy (52) , but it may reduce hospitalizations (53) . Unless there is direct evidence of benefit of a goal-oriented approach in a randomized trial setting, such an approach could lead to unnecessary overtreatment. Thus, further studies are of paramount importance in determining whether a low-risk goal-oriented strategy is superior to the current treatment paradigm (1, 2) . A randomized, prospective, parallelgroup trial could compare the effect of a goal-oriented treatment strategy with standard care on currently accepted composite clinical endpoints (34, 41, 42) . The experimental arm could involve rapid addition of medications or dose uptitration over a short-term period (e.g., 1 yr) for those not obtaining a low-risk profile, compared with a strategy of initial monotherapy (for NYHA class I-II patients) or upfront combination therapy (for NYHA class III-IV patients) (54) . Because individual responses vary greatly, a goal-oriented strategy could actually be more efficient and less costly than a universal strategy of initial dual or triple therapy for all newly diagnosed patients. A binary primary endpoint could be considered as a low-risk REVEAL score (,8 vs. >8), a summary score (low risk, 1; intermediate risk, 2; high risk, 3) rounded to the nearest integer using the ESC/ERS tool (1 vs. .1), or the number of low-risk criteria present (three or four criteria present vs. fewer than three criteria). Neither the REVEAL score nor the ESC/ERS tool absolutely requires invasive hemodynamic variables (12, 25) ; therefore, a simplified noninvasive approach could also be a feasible endpoint option. We suggest that a minimum of three variables be included when using the ESC/ERS tool, one of which should be a direct indicator of RV function (i.e., hemodynamic variables, BNP/NT-proBNP, or an imaging-derived measure of RV function). Unlike REVEAL, the ESC/ERS tool has not yet been validated in prevalent patients more than 1 year from diagnosis, which represented the majority of participants in recent phase III studies of macitentan and selexipag (41, 42) . It is also of interest whether other hemodynamic variables, such as the stroke volume index, and cardiac magnetic resonance imaging-derived or echocardiographyderived measures of RV function improve discrimination of risk within the first year and can refine the definition of "low risk" before adoption of these risk tools as a trial endpoint (48, 55, 56) . Several types of analyses are possible using a low-risk profile endpoint. Although some patients with incident PAH fall into a low-risk category at the time of diagnosis or Proposed schematic for a randomized controlled trial design using a low-risk profile as a primary endpoint. Randomization may be stratified by baseline risk category with periodic reassessments of risk over time in a time-to-event analysis, or the proportion of patients achieving or maintaining a low-risk profile at a short to intermediate fixed duration (e.g., 12 mo) from randomization could be used as the primary outcome. ESC/ERS = European Society of Cardiology/European Respiratory Society; PAH = pulmonary arterial hypertension; REVEAL = Registry to Evaluate Early and Long-term PAH Disease Management score. trial enrollment, they were a significant minority in the European and REVEAL studies. Therefore, a time-to-event (i.e., time to obtaining a low-risk profile) analysis could be used in a study that excludes patients who are low risk at baseline. However, the maintenance or achievement of a low-risk status is also an important treatment objective to study, because the absence of clinical deterioration is implicit ( Figure 1C) . Alternatively, the proportion of patients who have a low-risk profile in a given follow-up period (e.g., 12 mo) could be a primary endpoint, with randomization stratified by baseline risk group, allowing the inclusion of all patients, regardless of risk category at baseline (Figure 3) . Compared with the event-driven methodology used in recent landmark PAH trials, using the proportion of patients with a low-risk profile in a given follow-up period (i.e., 12 mo) could permit shorter-duration trials, which should reduce cost and decrease the chance of dropout or crossover, helping to maintain statistical power. This approach will be particularly important and complimentary to the emerging era of precision medicine in PAH, which will no doubt yield many promising but expensive new options for treating PAH (14, (57) (58) (59) . Because the number of patients with PAH available for clinical studies is limited, molecular phenotyping approaches may allow researchers to enrich trials with patients who are more likely to respond to a given experimental intervention. For example, characterization of endothelin 1 pathway polymorphisms may help to enrich future trials evaluating therapies targeting the endothelin 1 pathway with patients more likely to benefit from those agents (60) . Characterization of bone morphogenetic protein receptor 2 expression could potentially help select participants more likely to respond to interventions targeting that pathway (61) . More precise patient selection and the development of robust surrogate outcomes would help to more efficiently evaluate a larger number of new therapies for the next generation of patients with PAH.
Even if the low-risk profile is validated, it is unknown whether regulatory agencies such as the Food and Drug Administration or the European Medicines Agency will consider it as an acceptable clinical, intermediate, or surrogate endpoint in future phase III studies (62, 63) . On the basis of the discussion above, we contend that the lowrisk profile more importantly reflects accepted treatment goals and strategies than TTCW or isolated variables such as changes in exercise capacity. To determine whether the low-risk profile has value beyond its individual components or is a valid surrogate for long-term outcomes, future studies should consider it as a secondary outcome or as part of a composite primary outcome. In this way, future pooled analyses might clarify its validity and appropriateness as a surrogate for clinical outcomes.
Conclusions
Regular multidimensional risk assessment is important to help predict prognosis and to guide therapeutic decisions for patients with PAH. Validated tools such as the REVEAL score or the ESC/ERS risk assessment table can be used not only to quickly and accurately gauge the short-and long-term risk of death for a patient but also to define a low-risk profile, which can be used as a treatment goal. Given the association with long-term survival in observational studies, the low-risk profile could be a relevant primary outcome for future clinical trials, but it requires further validation, likely in the context of a study designed specifically to test the superiority of a goal-oriented strategy. There is an urgent need to develop new treatment options for patients with PAH, but limited availability of patients and improvements in available medical therapies will make it increasingly difficult to power large-scale randomized controlled trials to detect an effect on mortality and other major morbidity events. If validated as an acceptable surrogate outcome, future clinical trial designs might incorporate meaningful multidimensional risk scores to improve clinical trial efficiency in terms of size, duration, and cost. n
